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Objective
Classic infantile Pompe disease affects many tissues,
including the brain. Untreated infants die within their
first year. While enzyme-replacement therapy (ERT) sig-
nificantly increases survival, its potential limitation is
that the drug cannot cross the bloodbrain- barrier. We
therefore investigated long-term cognitive development
in patients treated with ERT.
Methods
We prospectively assessed cognitive functioning in 10
children with classic infantile Pompe disease who had
been treated with ERT since 1999. Until 2004, infants
and young children were assessed with the Bayley Scales
of Infant Development (BSID-II; number of tests = 23).
After 2004, we switched to the Griffiths Mental Devel-
opmental Scales (Griffiths; number of tests = 19),
expecting it to differentiate better between various
domains. Older children were assessed using the Wechs-
ler Intelligence Scales for Children (WISC-III; number
of tests = 5). For children with tetraplegia, we used the
Raven Colored or Standard Progressive Matrices (num-
ber of tests = 3). For those with impaired hearing, we
used the Snijders Oomen Nonverbal Intelligence test-
Revised (SON-R 2½-7, number of tests = 1). In total, 51
tests were performed. Brain imaging was performed in
six children.
Results
During the first four years of life, developmental scores
in 10 children ranged from above average development
to severe developmental delay; they were influenced by
the type of intelligence test used, severity of motor
problems, speech/language difficulties and age at start of
therapy. Five of the children were also tested from five
years onwards. Among them were two tetraplegic chil-
dren whose earlier scores had indicated severe develop-
mental delay. These scores now ranged between normal
and mild developmental delay, and indicated that at
young age poor motor functioning may interfere with
proper assessment of cognition. We found delayed pro-
cessing speed in two children. Brain imaging revealed
periventricular white-matter abnormalities in four.
Conclusion
Cognitive development at school age ranged between
normal and mildly delayed in our long-term survivors
with classic infantile Pompe disease treated with ERT.
The oldest was 12 years. We found that cognition is
easily underestimated in children under five with poor
motor functioning.
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